Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

DCPH - Deciphera Pharmaceuticals, Inc.


IEX Last Trade
12.94
0.120   0.927%

Share volume: 346,158
Last Updated: Tue 08 Aug 2023 09:59:58 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): -0.11%

PREVIOUS CLOSE
CHG
CHG%

$12.82
0.12
0.94%
This ticker is disabled and data are no longer maintained and up to date.
Fundamental analysis
23%
Profitability 22%
Dept financing 6%
Liquidity 74%
Performance 15%
Company vs Stock growth
vs
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$12.94
P/E Ratio 
0.00
DAY RANGE
N/A - $13.08
EPS 
-$2.29
52 WEEK RANGE
$0.00 - $0.00
52 WEEK CHANGE
$0.00
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
86.476 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$0
AVERAGE 30 VOLUME 
$0
Company detail
CEO: Steven L. Hoerter
Region: US
Website: deciphera.com
Employees: 300
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST)

Recent news